{"docstore/data": {"ccd5b091-e4e7-4315-818e-81cf86f829fa": {"__data__": {"id_": "ccd5b091-e4e7-4315-818e-81cf86f829fa", "embedding": null, "metadata": {"document_title": "Common Side Effects of Keytruda: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2c42928-6689-46c3-b717-c9369bbc6c54", "node_type": "4", "metadata": {}, "hash": "e5a39cfff146f563f89b2818c0eff8c96284c5f2ef84443f0245b56e5852daf4", "class_name": "RelatedNodeInfo"}}, "text": "What are the common side effects of Keytruda? Common side effects include fatigue, nausea, and skin rash.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 105, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f9b1e58-a9cd-473b-89bc-2390262fcdf4": {"__data__": {"id_": "0f9b1e58-a9cd-473b-89bc-2390262fcdf4", "embedding": null, "metadata": {"document_title": "Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bb827372-e284-4587-8a3c-e48ba04f4e31", "node_type": "4", "metadata": {}, "hash": "c73be1b4e2cb5e6157fd80000f0fe59f6ca8631fa4924c5ed0be7dd3180c3218", "class_name": "RelatedNodeInfo"}}, "text": "Can Keytruda cause immune-related adverse effects? Yes, Keytruda can cause immune-related adverse effects such as colitis, hepatitis, and pneumonitis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 150, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e76e41-0aae-4eb3-b21b-2828a04a98b5": {"__data__": {"id_": "41e76e41-0aae-4eb3-b21b-2828a04a98b5", "embedding": null, "metadata": {"document_title": "Safety of Keytruda in Pregnancy: A Comprehensive Review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "88725c45-d708-4986-979a-19250a4f8405", "node_type": "4", "metadata": {}, "hash": "583eb4caa1acdd76a69a5a2568c582a8d1b24bf01b5232055a763bb6cd4b00a1", "class_name": "RelatedNodeInfo"}}, "text": "Is Keytruda safe for pregnant women? Keytruda is not recommended for use during pregnancy due to potential risks to the fetus.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 126, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "245894c5-bae9-41f9-8aa9-599abef18560": {"__data__": {"id_": "245894c5-bae9-41f9-8aa9-599abef18560", "embedding": null, "metadata": {"document_title": "The Importance of Reporting Symptoms on Keytruda Treatment: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef95374a-9e15-4bb6-b0f0-f22951da49a3", "node_type": "4", "metadata": {}, "hash": "ece4cc1d01c5ca9149d1021a1bef61325dc0d0ddc383e236acdc57517e0e59cf", "class_name": "RelatedNodeInfo"}}, "text": "What should patients report immediately while on Keytruda treatment? Patients should report any new or worsening symptoms such as cough, chest pain, or changes in vision immediately.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 182, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5917cd7b-bc6b-4944-b93a-1dbb1a9f6aad": {"__data__": {"id_": "5917cd7b-bc6b-4944-b93a-1dbb1a9f6aad", "embedding": null, "metadata": {"document_title": "Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c50217c5-c3b6-4d08-bfd9-5f2a142f3907", "node_type": "4", "metadata": {}, "hash": "1647b8ddf165cd4ee7bacab5592a24b4855623ccc473132a13c588692b32adef", "class_name": "RelatedNodeInfo"}}, "text": "Are there any known interactions between Keytruda and other medications? Yes, Keytruda can interact with steroids and certain immunosuppressants, potentially affecting its efficacy and safety.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 192, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbe74f28-ac6c-4c9c-97e2-7f119bbbee4a": {"__data__": {"id_": "fbe74f28-ac6c-4c9c-97e2-7f119bbbee4a", "embedding": null, "metadata": {"document_title": "The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "172eb440-975b-4157-ace5-41722fc53e72", "node_type": "4", "metadata": {}, "hash": "c94df6025cefcf1493fb5461c551250192d9938b7a0b3fae81bbd7dd0dfa9dd6", "class_name": "RelatedNodeInfo"}}, "text": "How effective is Keytruda in treating non-small cell lung cancer? Keytruda has shown to improve survival rates significantly in non-small cell lung cancer patients with PD-L1 expression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 186, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2336f12c-2c65-40ff-b351-4fe4ef24ff44": {"__data__": {"id_": "2336f12c-2c65-40ff-b351-4fe4ef24ff44", "embedding": null, "metadata": {"document_title": "Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5752aa51-ae6c-4c87-ba2f-f0677b24d500", "node_type": "4", "metadata": {}, "hash": "eeb978316d5f07d2b6c828a5ab96c5fb04c5a0dde90346ba8100320f7035a8ca", "class_name": "RelatedNodeInfo"}}, "text": "What is the response rate of melanoma patients treated with Keytruda? Approximately 40% of melanoma patients respond positively to Keytruda treatment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 150, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0dd77f5-8ded-4b6f-82f0-5cb889ab8899": {"__data__": {"id_": "b0dd77f5-8ded-4b6f-82f0-5cb889ab8899", "embedding": null, "metadata": {"document_title": "\"Keytruda's Efficacy in Various Cancer Types: A Comprehensive Review\""}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4fd47ca5-b048-4a17-b809-a2a31931bd7f", "node_type": "4", "metadata": {}, "hash": "211fd7fe5d712aa71ad65225538e8c34784a890315e2295a6f2d3c0ec5b2a05c", "class_name": "RelatedNodeInfo"}}, "text": "Does Keytruda work for all types of cancer? Keytruda is most effective in cancers that express PD-L1 and in a genetic background favorable to immune therapy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 157, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911e722d-f028-49a3-8e89-15c1395c8340": {"__data__": {"id_": "911e722d-f028-49a3-8e89-15c1395c8340", "embedding": null, "metadata": {"document_title": "\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\""}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "864e6e8c-a391-4e9e-9da0-e34b8566bda8", "node_type": "4", "metadata": {}, "hash": "e603b5a6c3801d39d0f5cf61121c09f7b5b31749c5814f1b476627cdd8084a6e", "class_name": "RelatedNodeInfo"}}, "text": "How long does it take to see the effects of Keytruda in treating cancer? Some patients may see effects as early as 2 to 3 months into the treatment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 148, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11fdbfb1-55d7-4ea8-bed8-2763f6997b44": {"__data__": {"id_": "11fdbfb1-55d7-4ea8-bed8-2763f6997b44", "embedding": null, "metadata": {"document_title": "Keytruda and Lung Cancer: Five-Year Survival Rate Analysis"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93101cef-5c3d-4415-a83e-a38be36d8583", "node_type": "4", "metadata": {}, "hash": "cc5f7e805e3eb8dc3bac1c5bb409348154aa1b6ea31e5ed498c08c45fea6ed1b", "class_name": "RelatedNodeInfo"}}, "text": "What is the five-year survival rate for patients using Keytruda for lung cancer? No detailed information aviable on the given topic.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 132, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f15e19a-9d11-4f07-b8c9-e7922aca4b2d": {"__data__": {"id_": "6f15e19a-9d11-4f07-b8c9-e7922aca4b2d", "embedding": null, "metadata": {"document_title": "Objective Response Rate in KEYNOTE-006 Trial: A Comprehensive Analysis of Treatment Efficacy and Outcomes"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fa939e41-dfa7-4913-bced-96719309242e", "node_type": "4", "metadata": {}, "hash": "e51d19658e3d981b101980b0178c9c730f4f338c007233339cf751dc36d24f9b", "class_name": "RelatedNodeInfo"}}, "text": "What was the objective response rate in the KEYNOTE-006 trial? The provided response do not offer detailed information on the given topic.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 138, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d19d42c9-cbb5-4d03-b84d-d95dbfd10b70": {"__data__": {"id_": "d19d42c9-cbb5-4d03-b84d-d95dbfd10b70", "embedding": null, "metadata": {"document_title": "Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dfd90df5-d270-4809-b8cb-66c696f735db", "node_type": "4", "metadata": {}, "hash": "8ece3cf9c35dc00341732316c58b9e50d78e2c1e752cb31e55dc92bfdfd0598d", "class_name": "RelatedNodeInfo"}}, "text": "Are there any specific monitoring protocols for NSCLC patients on Keytruda as suggested by KEYNOTE-006 outcomes? Regular monitoring of liver function, lung function, and immune markers is recommended to manage potential side effects effectively.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 245, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31634d59-fb65-4d8e-b089-74194c5578f7": {"__data__": {"id_": "31634d59-fb65-4d8e-b089-74194c5578f7", "embedding": null, "metadata": {"document_title": "Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "878d7db0-26c6-4017-9619-400adf12af6b", "node_type": "4", "metadata": {}, "hash": "a09dfd6a82cdfee88b2c5772f18613aa634b9ec8cbb9de170d6db265970189f4", "class_name": "RelatedNodeInfo"}}, "text": "What was the impact of Keytruda on metastatic NSCLC in the KEYNOTE-051 trial? Keytruda significantly reduced the progression of metastatic disease and improved survival rates in metastatic NSCLC patients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 204, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "800ceedf-2019-4abc-80bd-e6b18bd68a5f": {"__data__": {"id_": "800ceedf-2019-4abc-80bd-e6b18bd68a5f", "embedding": null, "metadata": {"document_title": "KEYNOTE-10086 Trial Primary Endpoint Results: A Comprehensive Analysis"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9c63d67a-c9ef-47fa-89d1-e2373af1d8a2", "node_type": "4", "metadata": {}, "hash": "4a44e11d634f86e606d4ac2c0cfcbf0265eaad5b167c4969a7168831538b156e", "class_name": "RelatedNodeInfo"}}, "text": "Did the KEYNOTE-10086 trial meet its primary endpoints? No detailed information aviable on the given topic.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 107, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d54792e3-ac3f-4f90-8cfc-131f187fa429": {"__data__": {"id_": "d54792e3-ac3f-4f90-8cfc-131f187fa429", "embedding": null, "metadata": {"document_title": "Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d1522ed7-a2d9-42b9-849b-48d7cff322db", "node_type": "4", "metadata": {}, "hash": "52217f9f5838b33448bea23a48004bd2620c4e6e5da0e6ef582fb74435b671ff", "class_name": "RelatedNodeInfo"}}, "text": "What were the side effects noted in the KEYNOTE-006 trial? Common side effects included fatigue, itching, and diarrhea.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 119, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "683f95e2-960b-47aa-93fc-d964eca80c8b": {"__data__": {"id_": "683f95e2-960b-47aa-93fc-d964eca80c8b", "embedding": null, "metadata": {"document_title": "Keytruda Dosage Recommendations for Melanoma Treatment"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1bc67592-6666-4562-bc3d-f188fc712565", "node_type": "4", "metadata": {}, "hash": "398aec4e73b60ec219102c812038d8f71b49e6f1289cdd58ee8d1f40b515e6de", "class_name": "RelatedNodeInfo"}}, "text": "What is the recommended dosage of Keytruda for melanoma? The recommended dosage is 200 mg every three weeks for adults.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 119, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "334ad222-ae0e-43c2-b3a5-66b9bb84f630": {"__data__": {"id_": "334ad222-ae0e-43c2-b3a5-66b9bb84f630", "embedding": null, "metadata": {"document_title": "Advancing NSCLC Treatment: Immunotherapy Combinations, Personalized Medicine, and Overcoming Resistance in Non-Small Cell Lung Cancer"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d0defe37-9239-4daa-b71e-03f7fc35dcd7", "node_type": "4", "metadata": {}, "hash": "a7c22d49a8b46e18e69014e8b2aaea4c4b8925a3b7e987c38ab105a61aaecd7d", "class_name": "RelatedNodeInfo"}}, "text": "How do the results of KEYNOTE-006 influence the future research directions for NSCLC treatment? The results encourage further research into immunotherapy combinations, personalized medicine based on genetic markers, and strategies to overcome resistance to PD-1 inhibitors", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 272, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f14a116-ddc4-4238-b8bf-460786995642": {"__data__": {"id_": "5f14a116-ddc4-4238-b8bf-460786995642", "embedding": null, "metadata": {"document_title": "Administration of Keytruda: Intravenous Infusion Over 30 Minutes - Guidelines and Recommendations"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44f02a79-0ef7-4bb7-854c-f32265c47254", "node_type": "4", "metadata": {}, "hash": "1b49e5c862a94574d8068d5c00457f2698e05dd8c98cec8ee3c68720053a7ba9", "class_name": "RelatedNodeInfo"}}, "text": "How is Keytruda administered? Keytruda is administered as an intravenous infusion over 30 minutes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 98, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ef40478-30df-4a13-826a-dab8d6c2ab8a": {"__data__": {"id_": "7ef40478-30df-4a13-826a-dab8d6c2ab8a", "embedding": null, "metadata": {"document_title": "Combination Therapies with Keytruda for Cancer Treatment: A Comprehensive Overview"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2ab9c0ae-98bb-4171-b176-8535038881e4", "node_type": "4", "metadata": {}, "hash": "12a8d2b371d47dda014ac33af341be6d82415dd681b26dececc4838a7f330600", "class_name": "RelatedNodeInfo"}}, "text": "Can Keytruda be used in combination with other therapies? Yes, Keytruda can be used in combination with chemotherapy and other immunotherapies depending on the cancer type.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 172, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50de3260-0319-451d-879b-667a97078b06": {"__data__": {"id_": "50de3260-0319-451d-879b-667a97078b06", "embedding": null, "metadata": {"document_title": "Guidelines for Keytruda in the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dc38f691-053e-4d92-b68d-123703eaa731", "node_type": "4", "metadata": {}, "hash": "74ca0cad5d3066e93179bf0032fa6ddfd1525d1d506296b91f301f7b1c92b67d", "class_name": "RelatedNodeInfo"}}, "text": "What are the guidelines for Keytruda in treating Hodgkin's lymphoma? Keytruda is recommended for relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 182, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a9829cc-c28f-43ef-bbfa-06dff4be0c59": {"__data__": {"id_": "2a9829cc-c28f-43ef-bbfa-06dff4be0c59", "embedding": null, "metadata": {"document_title": "Comprehensive Guide to Patient Support Programs for Keytruda Users"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "47349d0b-6e62-41fb-a493-e76c6a35c8a4", "node_type": "4", "metadata": {}, "hash": "dcbb6119cde742fa0a017f8d7d565192a86021347ad12f1fe6868d530d40cb9b", "class_name": "RelatedNodeInfo"}}, "text": "Are there patient support programs available for Keytruda users? Yes, there are several patient support programs that provide financial assistance and counseling services.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 171, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c8bda13-a23d-428a-97a8-7d5fd70486e0": {"__data__": {"id_": "3c8bda13-a23d-428a-97a8-7d5fd70486e0", "embedding": null, "metadata": {"document_title": "\"Empowering Patients: A Comprehensive Guide to Keytruda Advocacy, Clinical Trials, and Healthcare Education\""}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ce94938a-a169-4e82-90dd-7a5029417117", "node_type": "4", "metadata": {}, "hash": "881b752745ea7d303aa2183093e36b42005eeb24725981c38300159b76ff97a5", "class_name": "RelatedNodeInfo"}}, "text": "How is awareness being raised for Keytruda as a treatment option? Awareness is being raised through patient advocacy groups, clinical trial publications, and healthcare provider education programs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 197, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fbb93fb-2cad-4003-a301-51c9a85b45f6": {"__data__": {"id_": "6fbb93fb-2cad-4003-a301-51c9a85b45f6", "embedding": null, "metadata": {"document_title": "Keytruda Support Groups: Connecting Patients for Shared Experiences and Advice"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6fa83c74-29f9-4675-a603-58ab220a5379", "node_type": "4", "metadata": {}, "hash": "eb3f5ae6f374cc93ba105088a7e6f71e15ade3db30aaacc0daa77a017231d428", "class_name": "RelatedNodeInfo"}}, "text": "Is there a community support group for patients undergoing treatment with Keytruda? Yes, several online and local support groups are available for sharing experiences and advice.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 178, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7387c06d-47e8-4f66-abe3-8c312957fa0c": {"__data__": {"id_": "7387c06d-47e8-4f66-abe3-8c312957fa0c", "embedding": null, "metadata": {"document_title": "Comprehensive Education on Keytruda: Benefits, Risks, and Follow-Up"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b9d02347-59a0-4beb-afb9-6a51d03f2c40", "node_type": "4", "metadata": {}, "hash": "686b693be1f48bc18db21fcd4a928c3180cd73f4745d4dfd26a532a14c46aa5a", "class_name": "RelatedNodeInfo"}}, "text": "How do healthcare providers educate patients about the benefits and risks of Keytruda? Healthcare providers offer educational materials, detailed consultations, and regular follow-up to discuss treatment progress and side effects.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 230, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20ba6bc3-c053-42a0-bce8-99c8a23e8c5b": {"__data__": {"id_": "20ba6bc3-c053-42a0-bce8-99c8a23e8c5b", "embedding": null, "metadata": {"document_title": "Keytruda's Superiority in Improving Survival Rates for Non-Small Cell Lung Cancer (NSCLC) Patients: A Comprehensive Review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "60e9dd78-5194-4d1e-9273-4a79e17312e1", "node_type": "4", "metadata": {}, "hash": "3b1dad66a83bd670df1e309367e273229a37f197a7c87c715f495efc3276e4e9", "class_name": "RelatedNodeInfo"}}, "text": "How does Keytruda improve survival rates in NSCLC patients compared to traditional treatments? Keytruda has been shown to improve the overall survival rates by reducing the risk of death by about 40% compared to traditional chemotherapy in patients with high PD-L1 expression.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 276, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bcc59a1-22c7-4610-8b50-0ec5959a2472": {"__data__": {"id_": "5bcc59a1-22c7-4610-8b50-0ec5959a2472", "embedding": null, "metadata": {"document_title": "Keytruda and Blood Pressure Changes: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "872d1ac9-bbba-4532-b24f-69040029f8f7", "node_type": "4", "metadata": {}, "hash": "4b18e3384a842ce815e6bdce35bf79b0fff938dc138b2aea40bc50b5703eb955", "class_name": "RelatedNodeInfo"}}, "text": "Can Keytruda cause changes in blood pressure? Yes, fluctuations in blood pressure can occur, and patients should monitor their blood pressure regularly.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 152, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f00414-ca60-4013-bd39-c4419a50f84a": {"__data__": {"id_": "65f00414-ca60-4013-bd39-c4419a50f84a", "embedding": null, "metadata": {"document_title": "Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bf800e74-467a-4730-9547-ebeec3e9430d", "node_type": "4", "metadata": {}, "hash": "c836b84f73a24eb1651123703374f4762bd0bd27f62b0153ea405e07244ce7ef", "class_name": "RelatedNodeInfo"}}, "text": "Are there specific side effects of Keytruda that NSCLC patients should monitor? NSCLC patients should monitor for cough, shortness of breath, and chest pain, as these could indicate immune-related pneumonitis.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 209, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e165120-4817-4142-b127-be1675a54e52": {"__data__": {"id_": "7e165120-4817-4142-b127-be1675a54e52", "embedding": null, "metadata": {"document_title": "Keytruda's Effectiveness in NSCLC: A Comparison of Smokers and Non-Smokers in the KEYNOTE-051 Study"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "70e985fe-40c1-4715-b02d-18c4de54edf3", "node_type": "4", "metadata": {}, "hash": "a92e33ce473eccdad7f862c9576e2de492b488c9d926c9836e485c3163ea099b", "class_name": "RelatedNodeInfo"}}, "text": "How does Keytruda's effectiveness in NSCLC compare between smokers and non-smokers in KEYNOTE-051? The effectiveness was slightly higher in non-smokers, although significant benefits were still observed in smokers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 214, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fcb980c-4242-44b1-b8cb-715fff851d8d": {"__data__": {"id_": "8fcb980c-4242-44b1-b8cb-715fff851d8d", "embedding": null, "metadata": {"document_title": "Genetic Markers in NSCLC Patients: PD-L1 Expression and Tumor Mutational Burden in the KEYNOTE-006 Trial"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ccad6c17-7237-4918-950e-dbe9bc35fefa", "node_type": "4", "metadata": {}, "hash": "5afc1b0179b17898ce1ae7f5867485bb5aab4eadea037f76a8fbde9668b566a3", "class_name": "RelatedNodeInfo"}}, "text": "What genetic markers were studied in NSCLC patients during the KEYNOTE-006 trial? PD-L1 expression and tumor mutational burden were key genetic markers studied to assess the response to Keytruda", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 194, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2464284d-ecd2-48d2-ad82-732db74481fe": {"__data__": {"id_": "2464284d-ecd2-48d2-ad82-732db74481fe", "embedding": null, "metadata": {"document_title": "Genetic Markers for Keytruda Treatment in Non-Small Cell Lung Cancer Patients: A Comprehensive Review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aa40f9e0-ea1a-46e3-a3a0-5b6d4e0e41f9", "node_type": "4", "metadata": {}, "hash": "6b1475f3fe6f53a3ef88459d54d8b661bf7f377082a3935390bd592ea40f0cc7", "class_name": "RelatedNodeInfo"}}, "text": "What genetic markers are tested before starting Keytruda in NSCLC patients? PD-L1 expression is the primary marker tested; however, genetic testing may also include EGFR mutations and ALK rearrangements to determine the best treatment approach.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 244, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4060df93-d937-4e97-a3a5-ea480a03a253": {"__data__": {"id_": "4060df93-d937-4e97-a3a5-ea480a03a253", "embedding": null, "metadata": {"document_title": "The Impact of Smoking Status on Keytruda Treatment Outcome in Non-Small Cell Lung Cancer (NSCLC)"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "67f3f905-ceda-452a-9ca0-994accc28638", "node_type": "4", "metadata": {}, "hash": "7e22aa214b7ca9b4cc370732e64fe0f03b8d4398b4e84303efc15212761f148b", "class_name": "RelatedNodeInfo"}}, "text": "Is there a difference in treatment outcome with Keytruda between smokers and non-smokers with NSCLC? Studies have shown that smoking status does not significantly affect the efficacy of Keytruda, although individual responses can vary.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 235, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e91e247-332e-4664-a7b4-83608e606ef8": {"__data__": {"id_": "3e91e247-332e-4664-a7b4-83608e606ef8", "embedding": null, "metadata": {"document_title": "Treatment of NSCLC Patients with Brain Metastases Using Keytruda: A Comprehensive Review"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80c2a43b-6105-46a1-b3ef-bda1b5e31242", "node_type": "4", "metadata": {}, "hash": "473c19f8e08f4dad458c9324b04d890d68b306b29eedf95c765f6305256b0652", "class_name": "RelatedNodeInfo"}}, "text": "Can NSCLC patients with brain metastases be treated with Keytruda? Keytruda can be used in NSCLC patients with brain metastases, especially when systemic disease control is needed, but close monitoring for neurological symptoms is essential.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 241, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1d72977-8826-4eb8-ba08-4d682b3d66fc": {"__data__": {"id_": "e1d72977-8826-4eb8-ba08-4d682b3d66fc", "embedding": null, "metadata": {"document_title": "Treatment Options for Non-Responding NSCLC Patients: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3eec8f0d-3667-4795-a9a2-f44d3c0ecb1b", "node_type": "4", "metadata": {}, "hash": "53c0b1967dd5ba99d4c7ead9a19b9ad2ecd3df6d6e4ad6ae32ddc7c7a73f4e4f", "class_name": "RelatedNodeInfo"}}, "text": "What are the options if an NSCLC patient does not respond to Keytruda? For non-responders, options may include switching to different immunotherapy drugs, combination therapies with chemotherapy, or targeted therapies based on genetic mutations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 245, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bca7cfe3-52a4-42b7-b63c-b700dc384819": {"__data__": {"id_": "bca7cfe3-52a4-42b7-b63c-b700dc384819", "embedding": null, "metadata": {"document_title": "\"Keytruda's Synergistic Approach in Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Review\""}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "faf4c3ac-53e3-4932-94cf-deefdf8a5385", "node_type": "4", "metadata": {}, "hash": "0d5b90b6f05e5f043dcfe0b79950ef0294571dfc808c9fc452ff3dbf368de11e", "class_name": "RelatedNodeInfo"}}, "text": "How does Keytruda work in combination with other therapies for NSCLC?  Keytruda works synergistically with chemotherapy and other immunotherapies to enhance the immune response against cancer cells, often leading to improved outcomes.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 234, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "667f2c86-6a24-491e-8286-be9eef9d254e": {"__data__": {"id_": "667f2c86-6a24-491e-8286-be9eef9d254e", "embedding": null, "metadata": {"document_title": "Financial Support Options for Keytruda Treatment for NSCLC Patients: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cf7c7ff9-0960-44b2-a315-4a0aa02131ff", "node_type": "4", "metadata": {}, "hash": "5e3c3e728a3da7e86e03ab9b514bff2b82c29e2067601107b9b6118b8f44f43f", "class_name": "RelatedNodeInfo"}}, "text": "What are the financial support options for NSCLC patients needing Keytruda treatment? Financial support options include manufacturer assistance programs, insurance coverage support, and non-profit grants that help with the cost of treatment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 241, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03dc2556-93da-4d77-a330-4042c14d8e74": {"__data__": {"id_": "03dc2556-93da-4d77-a330-4042c14d8e74", "embedding": null, "metadata": {"document_title": "Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6439d816-c5cb-4bd1-b9ba-7df33b1496da", "node_type": "4", "metadata": {}, "hash": "b1e1969e11c284e71c9f2530c3e448ec900cd1a9391f7507ede56fd3401224f1", "class_name": "RelatedNodeInfo"}}, "text": "Can Keytruda cause fatigue in NSCLC patients? No detailed information aviable on the given topic.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 97, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b93d2325-2c44-49e7-9799-7a7f2ff11210": {"__data__": {"id_": "b93d2325-2c44-49e7-9799-7a7f2ff11210", "embedding": null, "metadata": {"document_title": "Advancements in Keytruda Research for Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Overview"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97e88aa3-32b9-4478-a1d6-715c781e99ec", "node_type": "4", "metadata": {}, "hash": "cf125648d249da4eb988708e8f21bbc4e57cb2bbb757d5ceccb70651cf736fb5", "class_name": "RelatedNodeInfo"}}, "text": "What advancements are being researched for Keytruda in NSCLC treatment? Ongoing research includes optimizing combination therapies, exploring lower doses, and extending its use to earlier stages of NSCLC.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 204, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd4ef810-3a53-4896-92e6-163fb356a72a": {"__data__": {"id_": "bd4ef810-3a53-4896-92e6-163fb356a72a", "embedding": null, "metadata": {"document_title": "The Impact of Keytruda on Immune System Function in Non-Small Cell Lung Cancer (NSCLC) Patients"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e9e74cc8-ddcb-457a-adbd-8b2ef4edb351", "node_type": "4", "metadata": {}, "hash": "e12b51245aa4983a9f49193844a23111cb167b4b00c8d446eb4db98f97a74af8", "class_name": "RelatedNodeInfo"}}, "text": "How does Keytruda affect immune system function in NSCLC patients? Keytruda enhances the immune system's ability to detect and destroy cancer cells but can also lead to immune-related adverse effects that need to be managed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 224, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4fc115f-e885-492e-b0dd-c7ae78785b66": {"__data__": {"id_": "c4fc115f-e885-492e-b0dd-c7ae78785b66", "embedding": null, "metadata": {"document_title": "Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9c096f22-e9e9-466f-9837-e4ff37e8aadc", "node_type": "4", "metadata": {}, "hash": "32af240e9f1d3da212ca6def5a4e93468a5c04d3f38f989501f5131ec2761d9e", "class_name": "RelatedNodeInfo"}}, "text": "What are the criteria for discontinuing Keytruda in NSCLC patients? Keytruda may be discontinued if there is significant disease progression, unacceptable toxicity, or upon patient decision in consultation with their healthcare provider.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 237, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee821129-c660-4e63-8f02-313330a080fc": {"__data__": {"id_": "ee821129-c660-4e63-8f02-313330a080fc", "embedding": null, "metadata": {"document_title": "Comparing Keytruda to Targeted Therapies in NSCLC Patients with Specific Genetic Alterations: Analysis of KEYNOTE-006 Study"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b1afdbb6-d1f8-49c9-9633-4290e9b03aa4", "node_type": "4", "metadata": {}, "hash": "c47a15b6d20e9981b51ff0f31f61646c70b92fe7b5750e6495b45b1ae18b67c8", "class_name": "RelatedNodeInfo"}}, "text": "How did Keytruda compare to targeted therapies in NSCLC patients with specific genetic alterations in KEYNOTE-006? Keytruda showed comparable efficacy to targeted therapies in patients without specific actionable genetic alterations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 233, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ebf8556-690c-4f6e-ba8f-1fc24524f51c": {"__data__": {"id_": "2ebf8556-690c-4f6e-ba8f-1fc24524f51c", "embedding": null, "metadata": {"document_title": "Positive Response to Keytruda in NSCLC: Tumor Reduction, Respiratory Improvement, and Enhanced Well-Being in Patients with Non-Small Cell Lung Cancer"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "133e85ca-bad9-4b68-8a79-f97db47bfb04", "node_type": "4", "metadata": {}, "hash": "88c382ad9222a2052c23403c6568abb17f7fa4f31c9e97c68ca8c67f56e5753f", "class_name": "RelatedNodeInfo"}}, "text": "What are the signs of a positive response to Keytruda in NSCLC? Signs include a decrease in tumor size on imaging, improvement in respiratory symptoms, and increased overall physical activity and well-being.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 207, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c8bcfaf-3375-4e6c-b4c0-5d315aa869ea": {"__data__": {"id_": "4c8bcfaf-3375-4e6c-b4c0-5d315aa869ea", "embedding": null, "metadata": {"document_title": "Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "61ef9801-85ec-43a7-9442-a20be45c51ee", "node_type": "4", "metadata": {}, "hash": "d6006a9d9525d8f9c40c21e1768057a9ab8ebe753bb9f9b1fbe831a9c6b62979", "class_name": "RelatedNodeInfo"}}, "text": "Can Keytruda be used in NSCLC patients with autoimmune diseases? Keytruda should be used with caution in patients with pre-existing autoimmune diseases due to the risk of exacerbating the condition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 198, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f04651cc-474e-4368-a47f-c2d9d1870682": {"__data__": {"id_": "f04651cc-474e-4368-a47f-c2d9d1870682", "embedding": null, "metadata": {"document_title": "Keytruda Outperforms Traditional Chemotherapy in Non-Small Cell Lung Cancer Survival Rates"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "82b109f4-6620-4105-815f-4fb2227b9825", "node_type": "4", "metadata": {}, "hash": "728fad05a5960f8892ac56f5751e0ca54f98a48b8015ac00fb326f26ef21243a", "class_name": "RelatedNodeInfo"}}, "text": "What are the survival rates for NSCLC patients treated with Keytruda compared to those treated with traditional chemotherapy? Survival rates are generally higher for patients treated with Keytruda, especially those with high PD-L1 expression, compared to traditional chemotherapy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 280, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc9ba042-bb5c-4e96-971f-bc6285420d70": {"__data__": {"id_": "cc9ba042-bb5c-4e96-971f-bc6285420d70", "embedding": null, "metadata": {"document_title": "Keytruda Treatment in NSCLC Patients: Complete Remission Rates in KEYNOTE-789 Study"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7d903b6d-c43c-4dcc-8139-7f68c13d6b60", "node_type": "4", "metadata": {}, "hash": "a2c68d5dcd92454cc53cabee934ac6dfa762349d42542ff7609d9f1855dca2db", "class_name": "RelatedNodeInfo"}}, "text": "What percentage of NSCLC patients experienced complete remission with Keytruda treatment in KEYNOTE-789? The provided information do not offer detailed information on the topic or questions self.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 195, "text_template": "[Excerpt from document]\n{metadata_str}\nExcerpt:\n-----\n{content}\n-----\n", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"ccd5b091-e4e7-4315-818e-81cf86f829fa": {"doc_hash": "590c5b42998d3db0dcd48d3af19cf521a5d69d1b7908d43c04ff4467a5e14fc4", "ref_doc_id": "c2c42928-6689-46c3-b717-c9369bbc6c54"}, "0f9b1e58-a9cd-473b-89bc-2390262fcdf4": {"doc_hash": "57af33af395f2a8468e0f4509fc75bf4dbedbcce55a1a8f2653b2f628161d271", "ref_doc_id": "bb827372-e284-4587-8a3c-e48ba04f4e31"}, "41e76e41-0aae-4eb3-b21b-2828a04a98b5": {"doc_hash": "42eadc5186dd23c1b509b2bd4b75f2ff73e95b884e4159d7836bf43f4f27e588", "ref_doc_id": "88725c45-d708-4986-979a-19250a4f8405"}, "245894c5-bae9-41f9-8aa9-599abef18560": {"doc_hash": "34b00065801488fa536472f98d3409ce29a542b9c017c2aba5fa705d4fd76010", "ref_doc_id": "ef95374a-9e15-4bb6-b0f0-f22951da49a3"}, "5917cd7b-bc6b-4944-b93a-1dbb1a9f6aad": {"doc_hash": "d27d21651cf492f026c28c17a0da86cda754687f60f7105ab377342baf746ae1", "ref_doc_id": "c50217c5-c3b6-4d08-bfd9-5f2a142f3907"}, "fbe74f28-ac6c-4c9c-97e2-7f119bbbee4a": {"doc_hash": "4e4e4cd3b6a09857151ab05fe2c7545fca9aa17c6d557bac7b4c6ea20b6ac385", "ref_doc_id": "172eb440-975b-4157-ace5-41722fc53e72"}, "2336f12c-2c65-40ff-b351-4fe4ef24ff44": {"doc_hash": "65b6c3a5a97b9d9bb4c659135ca27eef2c84e290991aa671dfedf819fc479ead", "ref_doc_id": "5752aa51-ae6c-4c87-ba2f-f0677b24d500"}, "b0dd77f5-8ded-4b6f-82f0-5cb889ab8899": {"doc_hash": "3e35ec6556ff9ef51f382d1c1bf75a2cd6ed4de52c2c635cd5bf77c52e6f9381", "ref_doc_id": "4fd47ca5-b048-4a17-b809-a2a31931bd7f"}, "911e722d-f028-49a3-8e89-15c1395c8340": {"doc_hash": "62b81e308f8106324fb50efa4f7bb27d9ada07a0d48f680b5df1a96edf8ac3c2", "ref_doc_id": "864e6e8c-a391-4e9e-9da0-e34b8566bda8"}, "11fdbfb1-55d7-4ea8-bed8-2763f6997b44": {"doc_hash": "c2a98214482d1eb9135cf570b2e5ce79353fe80b96e05b1ce934f62fe1bbcb36", "ref_doc_id": "93101cef-5c3d-4415-a83e-a38be36d8583"}, "6f15e19a-9d11-4f07-b8c9-e7922aca4b2d": {"doc_hash": "8f1c680127c21e4be4c4f8553fbe8872a7503aa1934fb95eac2cb4cb16d28cf2", "ref_doc_id": "fa939e41-dfa7-4913-bced-96719309242e"}, "d19d42c9-cbb5-4d03-b84d-d95dbfd10b70": {"doc_hash": "7a1237abdc6663806658320c1b69710289765112833d5545230fe21517561006", "ref_doc_id": "dfd90df5-d270-4809-b8cb-66c696f735db"}, "31634d59-fb65-4d8e-b089-74194c5578f7": {"doc_hash": "7982ded4a7569ada0eae7c20811008f889788b9bc7b28ec8b262a5f267fd087c", "ref_doc_id": "878d7db0-26c6-4017-9619-400adf12af6b"}, "800ceedf-2019-4abc-80bd-e6b18bd68a5f": {"doc_hash": "0bd8b19a34636d3fa6ceeb2c394c8b366637e22e908f54034d93799d01f28bde", "ref_doc_id": "9c63d67a-c9ef-47fa-89d1-e2373af1d8a2"}, "d54792e3-ac3f-4f90-8cfc-131f187fa429": {"doc_hash": "208d0597f1fb9b1f01e230bcfa4c67a304a326fea09de451d8da649c7fc24ab7", "ref_doc_id": "d1522ed7-a2d9-42b9-849b-48d7cff322db"}, "683f95e2-960b-47aa-93fc-d964eca80c8b": {"doc_hash": "53209b699f017435ad7dda14691c44dc4a34abb9a29620ffe6784fd6fde44534", "ref_doc_id": "1bc67592-6666-4562-bc3d-f188fc712565"}, "334ad222-ae0e-43c2-b3a5-66b9bb84f630": {"doc_hash": "7cc852dea5cd0545c8c6dc7a7cb8a274445c4118fd4037b795c371e229b125bb", "ref_doc_id": "d0defe37-9239-4daa-b71e-03f7fc35dcd7"}, "5f14a116-ddc4-4238-b8bf-460786995642": {"doc_hash": "7aafaee1413ee61deb351dea5fe6456b8ab6202aef6f3c0d542d3a8195a1968d", "ref_doc_id": "44f02a79-0ef7-4bb7-854c-f32265c47254"}, "7ef40478-30df-4a13-826a-dab8d6c2ab8a": {"doc_hash": "075e3a36b6e979e913b17a040e862e454fef6c8a1f39cafdbc748f428aa02ed2", "ref_doc_id": "2ab9c0ae-98bb-4171-b176-8535038881e4"}, "50de3260-0319-451d-879b-667a97078b06": {"doc_hash": "4c7c6fae964d0a7928d3fdd98a2b1b1e17f4d375d0778f8fd7d5e8c5d95d8d4c", "ref_doc_id": "dc38f691-053e-4d92-b68d-123703eaa731"}, "2a9829cc-c28f-43ef-bbfa-06dff4be0c59": {"doc_hash": "31c20aee098ac97b255c7d66bf9167fa76e509c1e4996f8f22ca44fa78a30454", "ref_doc_id": "47349d0b-6e62-41fb-a493-e76c6a35c8a4"}, "3c8bda13-a23d-428a-97a8-7d5fd70486e0": {"doc_hash": "5c0073f82ea0679f7016c9c72feb5b95939320fbd7f9fb170e2b57ad676c7978", "ref_doc_id": "ce94938a-a169-4e82-90dd-7a5029417117"}, "6fbb93fb-2cad-4003-a301-51c9a85b45f6": {"doc_hash": "f3a1e501266f6c26ff2fc85cb7107c20770da1099e4fbf86278e2cbe52beb548", "ref_doc_id": "6fa83c74-29f9-4675-a603-58ab220a5379"}, "7387c06d-47e8-4f66-abe3-8c312957fa0c": {"doc_hash": "503e05fca0560b8bb06e92140000b299c908f4fb5ee47bd1af172f7e45428f3a", "ref_doc_id": "b9d02347-59a0-4beb-afb9-6a51d03f2c40"}, "20ba6bc3-c053-42a0-bce8-99c8a23e8c5b": {"doc_hash": "071d3be0f56ed057d1f4582c4a800b824a17b7f5891e2a8d62159aa6bcb26492", "ref_doc_id": "60e9dd78-5194-4d1e-9273-4a79e17312e1"}, "5bcc59a1-22c7-4610-8b50-0ec5959a2472": {"doc_hash": "95189d653b7ca31bc329d9ac4353f4ceb4f25717a7a3aa8152e4a02b12208ee6", "ref_doc_id": "872d1ac9-bbba-4532-b24f-69040029f8f7"}, "65f00414-ca60-4013-bd39-c4419a50f84a": {"doc_hash": "3ac56eb6f9e9fc49d48e02b596366a294960a00dc98e7f3f38ca7b5e1d03f9f1", "ref_doc_id": "bf800e74-467a-4730-9547-ebeec3e9430d"}, "7e165120-4817-4142-b127-be1675a54e52": {"doc_hash": "42b29674537a72021e8606f02af12733cf3a5dd8d13c28b936e1096fd1bb62ac", "ref_doc_id": "70e985fe-40c1-4715-b02d-18c4de54edf3"}, "8fcb980c-4242-44b1-b8cb-715fff851d8d": {"doc_hash": "f5569b4f6630b5ba5c071b68098fefb122d132b18c9db7529f84e19d0b7e91a0", "ref_doc_id": "ccad6c17-7237-4918-950e-dbe9bc35fefa"}, "2464284d-ecd2-48d2-ad82-732db74481fe": {"doc_hash": "9c3e9743e9f1f9cab439e6d1ed475f7069dab61dc31ceb59a2a65baa2135ca8c", "ref_doc_id": "aa40f9e0-ea1a-46e3-a3a0-5b6d4e0e41f9"}, "4060df93-d937-4e97-a3a5-ea480a03a253": {"doc_hash": "255d1a624861c0d65be70b8cc780fa5dae5668cf678e17179992af937c5f62f8", "ref_doc_id": "67f3f905-ceda-452a-9ca0-994accc28638"}, "3e91e247-332e-4664-a7b4-83608e606ef8": {"doc_hash": "d0afe4857b98995dbf4425e6f142fb72a64efe1ad58e4eb722b54ea6981536f0", "ref_doc_id": "80c2a43b-6105-46a1-b3ef-bda1b5e31242"}, "e1d72977-8826-4eb8-ba08-4d682b3d66fc": {"doc_hash": "0a6748808d6a7fe17115f43355c2b800ce22592e19ae24b680443859874b8808", "ref_doc_id": "3eec8f0d-3667-4795-a9a2-f44d3c0ecb1b"}, "bca7cfe3-52a4-42b7-b63c-b700dc384819": {"doc_hash": "9a430c7dd1dc0c3458a2338ce572cc20786f2116f63e11c83c37da64e51a09f2", "ref_doc_id": "faf4c3ac-53e3-4932-94cf-deefdf8a5385"}, "667f2c86-6a24-491e-8286-be9eef9d254e": {"doc_hash": "5304e5fa1fe5aea10c9bc48e241c4b7c1253c5c0803fa8aa3fef97089f3be59b", "ref_doc_id": "cf7c7ff9-0960-44b2-a315-4a0aa02131ff"}, "03dc2556-93da-4d77-a330-4042c14d8e74": {"doc_hash": "0449d09d82f0c95b33dc00dbc05ed5eb87b82c38b092c30887e55dd08bf36733", "ref_doc_id": "6439d816-c5cb-4bd1-b9ba-7df33b1496da"}, "b93d2325-2c44-49e7-9799-7a7f2ff11210": {"doc_hash": "114a09bd6c660e8b8813bb41a66654534dd9135c6aa460b58046bd9c386d89da", "ref_doc_id": "97e88aa3-32b9-4478-a1d6-715c781e99ec"}, "bd4ef810-3a53-4896-92e6-163fb356a72a": {"doc_hash": "93f42fa02677433758e21a2daa80380af16d98ec2ce690dd0ae0cfc43919830f", "ref_doc_id": "e9e74cc8-ddcb-457a-adbd-8b2ef4edb351"}, "c4fc115f-e885-492e-b0dd-c7ae78785b66": {"doc_hash": "64e59dd6f2c3206ba734434dc33fe36f1b5d71cab5682cc839633185b45b7fe1", "ref_doc_id": "9c096f22-e9e9-466f-9837-e4ff37e8aadc"}, "ee821129-c660-4e63-8f02-313330a080fc": {"doc_hash": "b771c597f311a7ffaa749698c71a1e96be273d8370cea71adae69440f7edcdf4", "ref_doc_id": "b1afdbb6-d1f8-49c9-9633-4290e9b03aa4"}, "2ebf8556-690c-4f6e-ba8f-1fc24524f51c": {"doc_hash": "a6d51bc94e4ecfe2db19c4eebc1cd501d72f423c32b1220fddfc32c8e385787f", "ref_doc_id": "133e85ca-bad9-4b68-8a79-f97db47bfb04"}, "4c8bcfaf-3375-4e6c-b4c0-5d315aa869ea": {"doc_hash": "1b48d7b26748bc786787a029c4bb11e67b523479ce791fa266b55689d7bb6e15", "ref_doc_id": "61ef9801-85ec-43a7-9442-a20be45c51ee"}, "f04651cc-474e-4368-a47f-c2d9d1870682": {"doc_hash": "cece1d599b13705d97362c1693c6908dc1afe8d6635d976ddaddefb8d42cc324", "ref_doc_id": "82b109f4-6620-4105-815f-4fb2227b9825"}, "cc9ba042-bb5c-4e96-971f-bc6285420d70": {"doc_hash": "7969206cccf8c2038ab2d59fdb7addd61550185d7bf4cacfc5ae3248b10a2122", "ref_doc_id": "7d903b6d-c43c-4dcc-8139-7f68c13d6b60"}}, "docstore/ref_doc_info": {"c2c42928-6689-46c3-b717-c9369bbc6c54": {"node_ids": ["ccd5b091-e4e7-4315-818e-81cf86f829fa"], "metadata": {"document_title": "Common Side Effects of Keytruda: A Comprehensive Guide"}}, "bb827372-e284-4587-8a3c-e48ba04f4e31": {"node_ids": ["0f9b1e58-a9cd-473b-89bc-2390262fcdf4"], "metadata": {"document_title": "Keytruda and Immune-Related Adverse Effects: A Comprehensive Overview"}}, "88725c45-d708-4986-979a-19250a4f8405": {"node_ids": ["41e76e41-0aae-4eb3-b21b-2828a04a98b5"], "metadata": {"document_title": "Safety of Keytruda in Pregnancy: A Comprehensive Review"}}, "ef95374a-9e15-4bb6-b0f0-f22951da49a3": {"node_ids": ["245894c5-bae9-41f9-8aa9-599abef18560"], "metadata": {"document_title": "The Importance of Reporting Symptoms on Keytruda Treatment: A Comprehensive Guide"}}, "c50217c5-c3b6-4d08-bfd9-5f2a142f3907": {"node_ids": ["5917cd7b-bc6b-4944-b93a-1dbb1a9f6aad"], "metadata": {"document_title": "Interactions of Keytruda with Steroids and Immunosuppressants: A Comprehensive Guide"}}, "172eb440-975b-4157-ace5-41722fc53e72": {"node_ids": ["fbe74f28-ac6c-4c9c-97e2-7f119bbbee4a"], "metadata": {"document_title": "The Impact of Keytruda on Survival Rates in Non-Small Cell Lung Cancer Patients with PD-L1 Expression"}}, "5752aa51-ae6c-4c87-ba2f-f0677b24d500": {"node_ids": ["2336f12c-2c65-40ff-b351-4fe4ef24ff44"], "metadata": {"document_title": "Keytruda Treatment Response Rate in Melanoma Patients: A Comprehensive Review"}}, "4fd47ca5-b048-4a17-b809-a2a31931bd7f": {"node_ids": ["b0dd77f5-8ded-4b6f-82f0-5cb889ab8899"], "metadata": {"document_title": "\"Keytruda's Efficacy in Various Cancer Types: A Comprehensive Review\""}}, "864e6e8c-a391-4e9e-9da0-e34b8566bda8": {"node_ids": ["911e722d-f028-49a3-8e89-15c1395c8340"], "metadata": {"document_title": "\"Keytruda: Rapid Effects in Cancer Treatment - A Comprehensive Overview\""}}, "93101cef-5c3d-4415-a83e-a38be36d8583": {"node_ids": ["11fdbfb1-55d7-4ea8-bed8-2763f6997b44"], "metadata": {"document_title": "Keytruda and Lung Cancer: Five-Year Survival Rate Analysis"}}, "fa939e41-dfa7-4913-bced-96719309242e": {"node_ids": ["6f15e19a-9d11-4f07-b8c9-e7922aca4b2d"], "metadata": {"document_title": "Objective Response Rate in KEYNOTE-006 Trial: A Comprehensive Analysis of Treatment Efficacy and Outcomes"}}, "dfd90df5-d270-4809-b8cb-66c696f735db": {"node_ids": ["d19d42c9-cbb5-4d03-b84d-d95dbfd10b70"], "metadata": {"document_title": "Monitoring Protocols for NSCLC Patients on Keytruda: A Comprehensive Guide"}}, "878d7db0-26c6-4017-9619-400adf12af6b": {"node_ids": ["31634d59-fb65-4d8e-b089-74194c5578f7"], "metadata": {"document_title": "Keytruda's Impact on Metastatic NSCLC: Progression Reduction and Survival Improvement in Patients"}}, "9c63d67a-c9ef-47fa-89d1-e2373af1d8a2": {"node_ids": ["800ceedf-2019-4abc-80bd-e6b18bd68a5f"], "metadata": {"document_title": "KEYNOTE-10086 Trial Primary Endpoint Results: A Comprehensive Analysis"}}, "d1522ed7-a2d9-42b9-849b-48d7cff322db": {"node_ids": ["d54792e3-ac3f-4f90-8cfc-131f187fa429"], "metadata": {"document_title": "Side Effects in KEYNOTE-006 Trial: A Comprehensive Analysis"}}, "1bc67592-6666-4562-bc3d-f188fc712565": {"node_ids": ["683f95e2-960b-47aa-93fc-d964eca80c8b"], "metadata": {"document_title": "Keytruda Dosage Recommendations for Melanoma Treatment"}}, "d0defe37-9239-4daa-b71e-03f7fc35dcd7": {"node_ids": ["334ad222-ae0e-43c2-b3a5-66b9bb84f630"], "metadata": {"document_title": "Advancing NSCLC Treatment: Immunotherapy Combinations, Personalized Medicine, and Overcoming Resistance in Non-Small Cell Lung Cancer"}}, "44f02a79-0ef7-4bb7-854c-f32265c47254": {"node_ids": ["5f14a116-ddc4-4238-b8bf-460786995642"], "metadata": {"document_title": "Administration of Keytruda: Intravenous Infusion Over 30 Minutes - Guidelines and Recommendations"}}, "2ab9c0ae-98bb-4171-b176-8535038881e4": {"node_ids": ["7ef40478-30df-4a13-826a-dab8d6c2ab8a"], "metadata": {"document_title": "Combination Therapies with Keytruda for Cancer Treatment: A Comprehensive Overview"}}, "dc38f691-053e-4d92-b68d-123703eaa731": {"node_ids": ["50de3260-0319-451d-879b-667a97078b06"], "metadata": {"document_title": "Guidelines for Keytruda in the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma"}}, "47349d0b-6e62-41fb-a493-e76c6a35c8a4": {"node_ids": ["2a9829cc-c28f-43ef-bbfa-06dff4be0c59"], "metadata": {"document_title": "Comprehensive Guide to Patient Support Programs for Keytruda Users"}}, "ce94938a-a169-4e82-90dd-7a5029417117": {"node_ids": ["3c8bda13-a23d-428a-97a8-7d5fd70486e0"], "metadata": {"document_title": "\"Empowering Patients: A Comprehensive Guide to Keytruda Advocacy, Clinical Trials, and Healthcare Education\""}}, "6fa83c74-29f9-4675-a603-58ab220a5379": {"node_ids": ["6fbb93fb-2cad-4003-a301-51c9a85b45f6"], "metadata": {"document_title": "Keytruda Support Groups: Connecting Patients for Shared Experiences and Advice"}}, "b9d02347-59a0-4beb-afb9-6a51d03f2c40": {"node_ids": ["7387c06d-47e8-4f66-abe3-8c312957fa0c"], "metadata": {"document_title": "Comprehensive Education on Keytruda: Benefits, Risks, and Follow-Up"}}, "60e9dd78-5194-4d1e-9273-4a79e17312e1": {"node_ids": ["20ba6bc3-c053-42a0-bce8-99c8a23e8c5b"], "metadata": {"document_title": "Keytruda's Superiority in Improving Survival Rates for Non-Small Cell Lung Cancer (NSCLC) Patients: A Comprehensive Review"}}, "872d1ac9-bbba-4532-b24f-69040029f8f7": {"node_ids": ["5bcc59a1-22c7-4610-8b50-0ec5959a2472"], "metadata": {"document_title": "Keytruda and Blood Pressure Changes: A Comprehensive Guide"}}, "bf800e74-467a-4730-9547-ebeec3e9430d": {"node_ids": ["65f00414-ca60-4013-bd39-c4419a50f84a"], "metadata": {"document_title": "Monitoring Keytruda Side Effects in NSCLC Patients: A Comprehensive Guide"}}, "70e985fe-40c1-4715-b02d-18c4de54edf3": {"node_ids": ["7e165120-4817-4142-b127-be1675a54e52"], "metadata": {"document_title": "Keytruda's Effectiveness in NSCLC: A Comparison of Smokers and Non-Smokers in the KEYNOTE-051 Study"}}, "ccad6c17-7237-4918-950e-dbe9bc35fefa": {"node_ids": ["8fcb980c-4242-44b1-b8cb-715fff851d8d"], "metadata": {"document_title": "Genetic Markers in NSCLC Patients: PD-L1 Expression and Tumor Mutational Burden in the KEYNOTE-006 Trial"}}, "aa40f9e0-ea1a-46e3-a3a0-5b6d4e0e41f9": {"node_ids": ["2464284d-ecd2-48d2-ad82-732db74481fe"], "metadata": {"document_title": "Genetic Markers for Keytruda Treatment in Non-Small Cell Lung Cancer Patients: A Comprehensive Review"}}, "67f3f905-ceda-452a-9ca0-994accc28638": {"node_ids": ["4060df93-d937-4e97-a3a5-ea480a03a253"], "metadata": {"document_title": "The Impact of Smoking Status on Keytruda Treatment Outcome in Non-Small Cell Lung Cancer (NSCLC)"}}, "80c2a43b-6105-46a1-b3ef-bda1b5e31242": {"node_ids": ["3e91e247-332e-4664-a7b4-83608e606ef8"], "metadata": {"document_title": "Treatment of NSCLC Patients with Brain Metastases Using Keytruda: A Comprehensive Review"}}, "3eec8f0d-3667-4795-a9a2-f44d3c0ecb1b": {"node_ids": ["e1d72977-8826-4eb8-ba08-4d682b3d66fc"], "metadata": {"document_title": "Treatment Options for Non-Responding NSCLC Patients: A Comprehensive Guide"}}, "faf4c3ac-53e3-4932-94cf-deefdf8a5385": {"node_ids": ["bca7cfe3-52a4-42b7-b63c-b700dc384819"], "metadata": {"document_title": "\"Keytruda's Synergistic Approach in Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Review\""}}, "cf7c7ff9-0960-44b2-a315-4a0aa02131ff": {"node_ids": ["667f2c86-6a24-491e-8286-be9eef9d254e"], "metadata": {"document_title": "Financial Support Options for Keytruda Treatment for NSCLC Patients: A Comprehensive Guide"}}, "6439d816-c5cb-4bd1-b9ba-7df33b1496da": {"node_ids": ["03dc2556-93da-4d77-a330-4042c14d8e74"], "metadata": {"document_title": "Keytruda and Fatigue in NSCLC Patients: Understanding the Impact of Immunotherapy on Energy Levels"}}, "97e88aa3-32b9-4478-a1d6-715c781e99ec": {"node_ids": ["b93d2325-2c44-49e7-9799-7a7f2ff11210"], "metadata": {"document_title": "Advancements in Keytruda Research for Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Overview"}}, "e9e74cc8-ddcb-457a-adbd-8b2ef4edb351": {"node_ids": ["bd4ef810-3a53-4896-92e6-163fb356a72a"], "metadata": {"document_title": "The Impact of Keytruda on Immune System Function in Non-Small Cell Lung Cancer (NSCLC) Patients"}}, "9c096f22-e9e9-466f-9837-e4ff37e8aadc": {"node_ids": ["c4fc115f-e885-492e-b0dd-c7ae78785b66"], "metadata": {"document_title": "Criteria for Discontinuing Keytruda in Non-Small Cell Lung Cancer Patients: A Comprehensive Guide"}}, "b1afdbb6-d1f8-49c9-9633-4290e9b03aa4": {"node_ids": ["ee821129-c660-4e63-8f02-313330a080fc"], "metadata": {"document_title": "Comparing Keytruda to Targeted Therapies in NSCLC Patients with Specific Genetic Alterations: Analysis of KEYNOTE-006 Study"}}, "133e85ca-bad9-4b68-8a79-f97db47bfb04": {"node_ids": ["2ebf8556-690c-4f6e-ba8f-1fc24524f51c"], "metadata": {"document_title": "Positive Response to Keytruda in NSCLC: Tumor Reduction, Respiratory Improvement, and Enhanced Well-Being in Patients with Non-Small Cell Lung Cancer"}}, "61ef9801-85ec-43a7-9442-a20be45c51ee": {"node_ids": ["4c8bcfaf-3375-4e6c-b4c0-5d315aa869ea"], "metadata": {"document_title": "Keytruda Use in NSCLC Patients with Autoimmune Diseases: Caution Advised"}}, "82b109f4-6620-4105-815f-4fb2227b9825": {"node_ids": ["f04651cc-474e-4368-a47f-c2d9d1870682"], "metadata": {"document_title": "Keytruda Outperforms Traditional Chemotherapy in Non-Small Cell Lung Cancer Survival Rates"}}, "7d903b6d-c43c-4dcc-8139-7f68c13d6b60": {"node_ids": ["cc9ba042-bb5c-4e96-971f-bc6285420d70"], "metadata": {"document_title": "Keytruda Treatment in NSCLC Patients: Complete Remission Rates in KEYNOTE-789 Study"}}}}